Background
Troy Laboratories develops, manufactures and sells veterinary chemical products. Its former research and development scientist, Dr Yeakuty Jhanker, left Troy in January 2023 and joined direct competitor Randlab in November 2023. Troy separately sued Dr Jhanker, alleging that she had improperly accessed and used confidential information.
After receiving allegations that Dr Jhanker had offered Troy’s information to competitors, Troy examined her former work laptop. A forensic analysis indicated that USB devices had been connected and that files may have been copied, although—with one irrelevant exception—the analysis could not establish that particular files were transferred. Troy also identified Randlab registrations for products corresponding to Troy products and relied on expert evidence identifying unexplained similarities and changes in several Randlab formulations. Troy sought preliminary discovery under rule 7.23 of the Federal Court Rules 2011 to decide whether to sue Randlab for misuse of confidential information, copyright infringement and involvement in a possible contravention of section 183 of the Corporations Act 2001.
The Court’s Holding
Justice Owens held that Troy subjectively believed it might have claims against Randlab and that the belief was objectively reasonable in some respects. The Court did not conduct a mini-trial or determine that Randlab had misused Troy’s information. Instead, it found sufficient circumstantial support for possible claims concerning Randlab’s Frusemide, Xylazine and Meloxicam 40 products, while rejecting a reasonable basis for claims concerning the Vitamin C and Avenge + Fly products.
The Court allowed targeted discovery covering categories including reference-formulation research, comparative testing, pilot batches, development records, reverse-engineering material, specified documents containing or corresponding with Troy’s formulation information, research-and-development tax-incentive records, pre-employment communications between Randlab and Dr Jhanker, and limited post-employment communications. It refused or narrowed other categories, including the APVMA application category and patent-search requests, because they were not reasonably required to decide whether to commence proceedings. The parties were directed to submit proposed orders addressing discovery, costs, confidentiality and redactions.
Key Takeaways
- Preliminary discovery requires a reasonably based belief that a claim may exist, not proof that the claim ultimately will succeed.
- Discovery must be confined to documents reasonably necessary to overcome the applicant’s informational shortfall; documents that would merely be useful or desirable are insufficient.
- Sworn assertions and prior searches do not necessarily defeat discovery where the adequacy of those searches remains genuinely disputed.
Why It Matters
The decision illustrates how preliminary discovery can be used in confidential-information disputes when suspected misuse is supported mainly by circumstantial evidence and the decisive development records are controlled by a prospective defendant. It also shows that the Court will assess the evidentiary basis product by product and tailor discovery rather than authorize a broad investigation.